Scarica l'app Stockscreener
64.50
0.10%
0.054
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$64.45
Aprire:
$64.43
Volume 24 ore:
1.56M
Relative Volume:
0.25
Capitalizzazione di mercato:
$25.16B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
45.16
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+3.17%
1M Prestazione:
+6.76%
6M Prestazione:
-25.67%
1 anno Prestazione:
-20.26%
Intervallo 1D:
$64.09
$65.16
Intervallo di 1 settimana:
$62.23
$65.31
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
64.51 | 25.14B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.53 | 219.65B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.08 | 146.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.98 | 140.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.83 | 130.80B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.33 | 49.16B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DEXCOM, INC. (NASDAQ: DXCM) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Is DexCom Stock Underperforming the S&P 500? - Barchart.com
Fisher Asset Management LLC Decreases Holdings in DexCom, Inc. $DXCM - Defense World
How DexCom Inc. (DC4) stock trades after earnings2025 Earnings Surprises & High Return Stock Watch Alerts - Newser
DXCM DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, - GlobeNewswire
DXCM DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
DexCom (DXCM): Morgan Stanley Upgrades Rating to Overweight and - GuruFocus
DexCom Stock Upgraded. How the Glucose Monitor Maker Is ‘Turning a Corner.’ - Barron's
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DexCom (DXCM) Upgraded by Morgan Stanley with Increased Price Ta - GuruFocus
DexCom upgraded at Morgan Stanley on sorting out operational issues - Seeking Alpha
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
Analyst recommendations: Albemarle, Dexcom, T-Mobile, Alphabet, Micron… - MarketScreener
Morgan Stanley Upgrades DexCom to Overweight From Equalweight, Adjusts PT to $75 From $63 - MarketScreener
Advisors Asset Management Inc. Sells 1,259 Shares of DexCom, Inc. $DXCM - Defense World
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
DXCM Deadline: DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Levi & Korsinsky Urges DexCom, Inc. (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
DXCM CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Global Retirement Partners LLC Takes $472,000 Position in DexCom, Inc. $DXCM - Defense World
2025-11-29 | Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Reminds Investors of December 26, 2025 | NDAQ:DXCM | Press Release - Stockhouse
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - PR Newswire
Cash from investing activities of DexCom, Inc. – SIX:DXCM - TradingView
Diluted net income available to common stockholders of DexCom, Inc. – SIX:DXCM - TradingView
Berry Wealth Group LP Takes $251,000 Position in DexCom, Inc. $DXCM - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Does DexCom’s Recent 5% Jump Signal a Real Value Opportunity for 2025? - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Investors Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Synopsys, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
With DexCom, Inc. (NASDAQ:DXCM) It Looks Like You'll Get What You Pay For - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here’s Why Dexcom (DXCM) Traded Down in Q3 - Insider Monkey
DXCM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to ... - Bakersfield.com
Artificial Intelligence in Remote Patient Monitoring Market Projected to Reach $14.51 Billion by 2032, Growing at a CAGR of 27.52% - GlobeNewswire Inc.
Evercore ISI Begins Coverage on DexCom (NASDAQ:DXCM) - Defense World
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights - GlobeNewswire
DXCM INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of DexCom, Inc. - Business Wire
DexCom (DXCM): Positive Outlook Amid Medicare Payment Report - GuruFocus
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives - Business Wire
DXCM Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Shareholders of Securities Fraud Class Action Lawsuit Deadline - NewMediaWire
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join - GuruFocus
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - TradingView
Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat - Finviz
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM) - Insider Monkey
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):